Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project
Executive Summary
Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.
You may also be interested in...
Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset
AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.
Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology
Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.